| Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial MC Garassino, O Martelli, M Broggini, G Farina, S Veronese, E Rulli, ... The lancet oncology 14 (10), 981-988, 2013 | 594 | 2013 |
| Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study N Harbeck, P Rastogi, M Martin, SM Tolaney, ZM Shao, PA Fasching, ... Annals of Oncology 32 (12), 1571-1581, 2021 | 356 | 2021 |
| First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non–small-cell lung cancer: the TORCH randomized trial C Gridelli, F Ciardiello, C Gallo, R Feld, C Butts, V Gebbia, P Maione, ... Journal of Clinical Oncology 30 (24), 3002-3011, 2012 | 278 | 2012 |
| Triple positive breast cancer: a distinct subtype? P Vici, L Pizzuti, C Natoli, T Gamucci, L Di Lauro, M Barba, D Sergi, ... Cancer treatment reviews 41 (2), 69-76, 2015 | 158 | 2015 |
| Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center A Fabi, A Felici, G Metro, A Mirri, E Bria, S Telera, L Moscetti, M Russillo, ... Journal of experimental & clinical cancer research 30, 1-7, 2011 | 152 | 2011 |
| Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC) F Di Costanzo, P Carlini, L Doni, B Massidda, R Mattioli, A Iop, E Barletta, ... British journal of cancer 93 (2), 185-189, 2005 | 139 | 2005 |
| Natural history of non-small-cell lung cancer with bone metastases D Santini, S Barni, S Intagliata, A Falcone, F Ferraù, D Galetta, L Moscetti, ... Scientific reports 5 (1), 1-9, 2015 | 130 | 2015 |
| Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era A Toss, C Isca, M Venturelli, C Nasso, G Ficarra, V Bellelli, C Armocida, ... ESMO open 6 (2), 100055, 2021 | 99 | 2021 |
| Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial S De Placido, C Gallo, M De Laurentiis, G Bisagni, G Arpino, MG Sarobba, ... The Lancet Oncology 19 (4), 474-485, 2018 | 99 | 2018 |
| Up‐front chemotherapy and radiation treatment in newly diagnosed nonsmall cell lung cancer with brain metastases: Survey by Outcome Research Network for Evaluation of Treatment … L Moscetti, F Nelli, A Felici, M Rinaldi, S De Santis, G D'Auria, G Mansueto, ... Cancer 109 (2), 274-281, 2007 | 89 | 2007 |
| Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going C Omarini, G Guaitoli, S Pipitone, L Moscetti, L Cortesi, S Cascinu, ... Cancer management and research, 91-103, 2018 | 79 | 2018 |
| A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience P Vici, L Pizzuti, A Michelotti, I Sperduti, C Natoli, L Mentuccia, L Di Lauro, ... Oncotarget 8 (34), 56921, 2017 | 72 | 2017 |
| T-DM1 and brain metastases: clinical outcome in HER2-positive metastatic breast cancer A Fabi, D Alesini, E Valle, L Moscetti, R Caputo, M Caruso, L Carbognin, ... The Breast 41, 137-143, 2018 | 69 | 2018 |
| Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a … D Miles, E Ciruelos, A Schneeweiss, F Puglisi, T Peretz-Yablonski, ... Annals of Oncology 32 (10), 1245-1255, 2021 | 68 | 2021 |
| Intra-arterial liver chemotherapy and hormone therapy in malignant insulinoma: case report and review of the literature L Moscetti, R Saltarelli, R Giuliani, G Fornarini, M Bezzi, E Cortesi Tumori Journal 86 (6), 475-479, 2000 | 68 | 2000 |
| Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study P Vici, L Pizzuti, C Natoli, L Moscetti, L Mentuccia, A Vaccaro, D Sergi, ... Breast cancer research and treatment 147, 599-607, 2014 | 60 | 2014 |
| Targeting PI3K/AKT/mTOR pathway in breast cancer: from biology to clinical challenges K Cerma, F Piacentini, L Moscetti, M Barbolini, F Canino, A Tornincasa, ... Biomedicines 11 (1), 109, 2023 | 59 | 2023 |
| Current challenges in HER2-positive breast cancer F Puglisi, C Fontanella, V Amoroso, GV Bianchi, G Bisagni, C Falci, ... Critical Reviews in Oncology/Hematology 98, 211-221, 2016 | 59 | 2016 |
| Eribulin mesylate in pretreated breast cancer patients: a multicenter retrospective observational study T Gamucci, A Michelotti, L Pizzuti, L Mentuccia, E Landucci, I Sperduti, ... Journal of Cancer 5 (5), 320, 2014 | 59 | 2014 |
| Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study … J Gligorov, B Ataseven, M Verrill, M De Laurentiis, KH Jung, HA Azim, ... European Journal of Cancer 82, 237-246, 2017 | 56 | 2017 |
